Feature Article | Leen Kawas Highlights the Role of Venture Partners in Scaling Life Sciences Innovation

Leen Kawas argues that capital is not enough to move biotech from discovery to durable commercial success. At Propel Bio Partners, she is building an investor model that treats strategic expertise, networking, and hands-on operational guidance as core value, not extras. The appointment of healthcare technology veteran Laurie Heilmann as Venture Partner illustrates what that looks like in practice: embedded support on commercialization strategy, market expansion, partnerships, and scaling. The result is a support ecosystem designed to help scientist-founders bridge the gap between breakthrough science and real-world execution, while reducing the predictable bottlenecks that stall promising programs.

Read the Full Article Here